HVAC and GMP Environmental Control – for Pharmaceutical Clean Rooms

Tuesday April 16, 2024
1:00 pm – 2:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Roger Cowan

Environmental control of pharmaceutical clean rooms is essential to the manufacture of a quality product.  The definition of Environmental Control vs. Environmental Monitoring is discussed.  Control of such conditions as airborne particulate, microorganisms, temperature, humidity, differential pressure, airflow, air velocity and personnel  is crucial to protect the product from contamination. 

Therefore, the design, validation and ongoing monitoring of a clean room HVAC system  is necessary to assure the quality and safety of the pharmaceutical product.

Also, a proper understanding and testing of the clean room environment according to international regulatory standards is important from a compliance perspective.  

It is important that a clean room’s  HVAC system is fully understood, properly designed and properly validated.  If this is accomplished, it will provide the environmental control necessary to meet the regulatory particulate and microorganism levels necessary to manufacture quality pharmaceutical product.

Read More ...


FDA Contract Manufacturing Arrangements for Drugs: Quality Agreements — Their Relationship to Microbiological Issues

Wednesday April 17, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

Has your Company ever been in a situation where you find that a process requires Qualification, or an assay requires Validation and you and your Client do not have a clear understanding as to whom who should be paying for it?  And, as a result, you and your Client come to a stalemate and nothing is done?  And, to make matters worse, the FDA shortly arrives thereafter and cites both you and your Client for this non-compliance?  Through your participation in this webinar, you should arrive at an understanding of how to manage these situations and avoid the citations from which these situations arise by gaining an enhanced understanding of “Written Quality Agreements”.

Read More ...


Quality System Management Effectiveness

Thursday April 18, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Danielle DeLucy

Background:

In many Life Sciences companies, “quality” becomes a “buzz” word.  In an industry which is one of the most regulated in the world, quality should come first when a company wants to be productive.  If designed properly, quality management systems can help a company achieve its compliance goals and its business goals. With regulations from FDA, EU and others becoming more and more stringent, Companies must optimize resources to effectively achieve their quality goals and find their optimal balance between cost and risk. 

Read More ...


THE BACTERIAL ENDOTOXINS TEST (ISSUES AND SOLUTIONS) TO INCLUDE THE ISSUE OF LOW ENDOTOXIN RECOVERY (LER) AND TR 82 (PDA) AND GENERAL INFORMATION CHAPTER <1085>

Tuesday April 23, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

On Tuesday, July 12, 2011, the FDA posted on their web site a notice that they had withdrawn the 1987 Guideline on Validation of the Limulus Amebocyte Lysate Test as an End Product Endotoxin Test for Human Parenteral Drugs, Biological Products and Medical Devices. They advised that the 1987 Guideline is considered obsolete and does not reflect the Agency’s current thinking on the topic. In lieu of this document, the FDA advised that they would be issuing a Guidance for Industry on Pyrogen and Endotoxins Testing: Questions and Answers during the November/ December 2011 timeframe. After much delay, this NEW Guidance was released in June 2012.

Read More ...


TERMINALLY STERILIZED PHARMACEUTICAL PRODUCTS—PARAMETRIC RELEASE (NEW USP<1222>, November 2019) AND ITS RELATIONSHIP TO THE NEW BRITISH TERMINAL STERILIZATION METHODOLOGY (March 2019)

Wednesday April 24, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

Parametric release is defined as the release of terminally sterilized batches or lots of sterile products based upon compliance with the defined critical parameters of sterilization without having to perform the testing requirements under USP<71> Sterility Tests.

Parametric release becomes possible when the mode of sterilization is 1) very well understood, 2) the physical parameters of processing are well defined, predictable, and measurable, 3) and the lethality of the cycle has been microbiologically validated through the use of appropriate biological indicators or, in the case of ionizing radiation, the appropriate microbiological and dosimetric tests.

Read More ...


SOLVING STATISTICAL MYSTERIES – WHAT DOES THE FDA WANT?

Thursday April 25, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Ronald D. Snee, PhD

Use of statistics has been part of the FDA’s guidances and regulations for many years. Use of statistics is an integral part of the Jan 2011 FDA Process Validation Guidance. It can be argued that the FDA is looking for the pharma and biotech industries to make even greater use of statistical thinking and methods. Even with this long history, the use of statistics seems to be a source of uncertainty and anxiety for many. This presentation provides an overview of what it appears the FDA is looking for in the use statistics including examples and recommended approaches.

Read More ...


Best Practices for Deviation Investigations

Tuesday April 30, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Danielle DeLucy

Course Description:

This webinar will help attendees understand the fundamental steps of a deviation investigation with focus on using documents, interviews, and objective evidence to arrive at a root cause and a corrective and preventative action plan.  Learn how to identify and classify deviations for easier management and investigation.

Read More ...


Annual Laboratory Microbiology Training

Wednesday May 1, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

The Laboratory Environment, and, in particular, the Microbiology laboratory, have definite Annual GMP Training requirements that necessitate “refreshing” (see 21 CFR 210/211, Section 25). With a constant influx of new and revised FDA Guidances for Industry, USP General and General Information Chapters, ISO, Canadian and EU requirements, Standard Operating Procedures (SOPs) are always in flux. In addition, with a continuum of Form FDA 483 Observations and Warning Letters providing “new twists” to what is expected of the Microbiology Laboratory Environment, the studying of these FDA compliance documents from a microbiological perspective can be most helpful.

Read More ...


A Risk Assessment Approach to Address Fungal Spore Contamination in a Cell and Gene Therapy Cleanroom

Thursday May 2, 2024
12:00 Noon – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Jim Polarine

Abstract:

This seminar will cover a risk-based approach to an Aspergillus brasiliensis contamination in a Cell and Gene Therapy Cleanroom.  Details will be provided on how to follow a risk-based approach utilizing a fishbone diagram and the five whys centered on using good science.  The most common causes of contamination will be conveyed in case studies with fungal spore contamination.  New efficacy testing data will be covered on Chaetomium and Aspergillus.  A recent case study will be covered in detail as well as microbial identifications and how to utilize a risk-based approach.  Solutions are going to be conveyed on how to proactively prevent fungal contamination from reoccurring.

Read More ...


Effective Regulatory Inspections

Tuesday May 7, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Danielle DeLucy

Most Regulatory Agencies require firms to have written procedures in place to document production and process controls, better known as batch records. Additionally, there must be written procedures for a batch record review process that demonstrate compliance.

A strong batch record review system is essential in order to properly document all critical processing parameters that go along with the production and manufacture of pharmaceuticals, biologics, medical devices, etc.

 

Read More ...


Development of a Steam Autoclave Sterilization Validation Plan

Wednesday May 8, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

Terminal moist heat sterilization is presently considered the method of choice to ensure sterility.  All aqueous-based sterile products are subject to terminal moist heat sterilization unless the sterilization, itself, will degrade the product. This interactive, live Executive Conference Corp. (ECC) webinar is intended to provide manufacturers of pharmaceutical dosage forms as well as components (vials and stoppers) with guidance to establish the scientific effectiveness of moist heat sterilization processes. It has been developed as an overview of the elements of moist heat sterilization processes requiring evaluation and describes approaches to effectively accomplish this. This guideline, derived from Health Canada guidances, specifies the minimum documentation required to certify that moist heat sterilization processes have been thoroughly evaluated and are adequately controlled and validated.

Read More ...


MICROBIOLOGY FOR THE NON-MICROBIOLOGIST – AND THE MICROBIOLOGIST WHO DESIRES A GMP MICROBIOLOGICAL REFRESHER

Thursday May 9, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

With the increasing number of Regulatory Actions throughout North America to include Form FDA 483s and Warning Letters for both Active Pharmaceutical Ingredients (APIs) and finished product, it has become increasingly important for Companies and individuals manufacturing both non-sterile and sterile final products, to have a basic understanding of microbiology — regardless of the Department in which they work.  Every individual within varying Departments from Facilities to Manufacturing to Quality Control should understand the basics of microbiology and the issues that non-compliance can create.  Recently, a large multi-national pharmaceutical company was cited for the second time by the FDA for not determining that mold was growing on the “clean side” of the HEPA filters in an ISO Class 5 environment after it had been identified by mechanics several years previously.

Read More ...


How to Detect Lack of Data Integrity

Tuesday May 14, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Ronald D. Snee, PhD

Data are central to the development, manufacture and marketing of pharmaceuticals of all types. The renewed interest in data integrity raises questions regarding what is data integrity and how to assess it. Lack of data integrity comes in two forms: purposeful manipulation of the data to deceive and the inadvertent problems that occur in the production and analysis of data. Humans, equipment or both can be the source of the problem.

Read More ...


Pharmaceutical Compressed Air – Quality GMP Standards and Requirements

Thursday May 16, 2024
1:00 pm – 2:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Roger Cowan

Compressed air for pharmaceutical use is considered a critical utility as many of its applications involve direct contact with the pharmaceutical product.

The design, construction and monitoring of a compressed air system is essential for maintaining a quality system without contamination of the product.  

Proper testing of compressed air quality according to international standards is important for both validation and ongoing monitoring of the system.

Compressed air is often overlooked as a potential source of clean room and product contamination.  This webinar will give you an understanding of the different types of contamination inherent in compressed air and how to prevent each from affecting your particular system.

Read More ...


VALIDATION MASTER PLANNING (DEVELOPING A COMPREHENSIVE VALIDATION PACKAGE)

Wednesday May 22, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

Whether a Company is developing a new product or facility, the issue of a comprehensive Validation Package is essential to assure the timely completion of all activities.  A Validation Package is designed to satisfy both current domestic and international regulations, guidelines and policies for active pharmaceutical ingredients (APIs), drugs, biologics and devices and to verify equipment systems, utilities, software and processes are properly designed (DQ), installed (IQ), operate (OQ) and perform (PQ) in a consistent and controlled manner.

Read More ...


Effective Batch Record Review

Thursday May 23, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Danielle DeLucy

Most Regulatory Agencies require firms to have written procedures in place to document production and process controls, better known as batch records. Additionally, there must be written procedures for a batch record review process that demonstrate compliance.

A strong batch record review system is essential in order to properly document all critical processing parameters that go along with the production and manufacture of pharmaceuticals, biologics, medical devices, etc.

 

Read More ...


Risk Management of Raw Materials in a GMP Environment

Tuesday June 11, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

Risk management of raw materials in a cGMP environment is an area that is often overlooked as a Company develops new products. Depending on the product being developed, e.g., tablets and capsules vs. biotechnology products, as few as fifteen to twenty raw materials or as many as sixty need to be sourced and accepted before the process can be moved from initiation through completion. This live, interactive presentation will extensively review this area. It will also delve into the renewed issue of microbial and endotoxin contamination of these raw materials and why the FDA, EMA and Health Canada have recently focused on them.

Read More ...


Good Laboratory Practices (GLP) vs. Good Manufacturing Practices (GMPs)  — A Comparison and Contrast – “Why One Should Use Only GMP Facilities for Manufacturing and Testing”

Thursday June 13, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

Periodically one hears the comment that “a laboratory or a manufacturing facility meets 21 CFR Part 58 Good Laboratory Practices (GLP) and therefore they meet all of the cGMP requirements”. Contrary to popular belief, 21 CFR Part 58 is not the equivalent of 21 CFR 210/211 and does not meet the same requirements as 210/211. They (Part 58) do have the force of law and are not “watered down” GMPs.

Good Manufacturing Practices (cGMPs) represents that part of Quality Assurance that ensures that products are consistently produced and controlled to the Quality standard appropriate to their intended use and as required by the product specification.  They fall within the requirements of 21 CFR Parts 210/211 and support final product requirements for humans and animals.

Read More ...


Bioburden Control of Non-Sterile Drug Substances and Products– A New USP General Information Chapter

Wednesday June 19, 2024
12:00 pm – 1:30 pm (NY Time)

Register Now for Executive Conference Corporation webinar.

Instructor:  Barry A. Friedman, Ph.D

USP recently released a “General Information Chapter” describing bioburden control of non-sterile drug substances and products — a much anticipated area that has gained significant attention over the past half dozen years. The subject, “USP <1115> Bioburden Control of Nonsterile Drug Substances and Products”, has generated much controversy as non-sterile manufacturers have repeatedly asked the question “what degree of microbial cleanliness should I require with my non-sterile drug substances and products” and “how many microorganisms of a single genus may I have where USP<1111> has limits of either 100 or 1000 per gram”?  Efforts have been made to historically answer these questions within other USP Chapters to include USP<61>, USP<1111> and USP<1231> which have addressed both test methodologies and microbial counts allowed.  21 CFR 211 has also “weighed into” this fray with their various regulations but have not offered solutions. Quite often during lectures and seminars, the comment is overheard “With sterile products, it was so much simpler to provide a microbial answer because I have definitive endpoints”.

Read More ...